0DRV.LSE

Arcticzymes Technologies ASA

0DRV.LSE, UK

ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing. The company offers shrimp alkaline phosphatase for cleanup prior to Sanger sequencing and next generation sequencing processes; cod UNG for use in viral and other molecular diagnostic assays for the removal of contaminating dU-DNA; salt active nucleases for the removal of nucleic acids during manufacturing of viral vectors, recombinant proteins, and other reagents; and double-strand specific DNases and derived kits for the removal of double stranded DNA. It also provides DNA/RNA polymerases for technology development for life science, molecular diagnostics, NGS, and synthetic biology; proteinase for microbiological diagnostics and liquid biopsies; and ligases for joining nucleic acids. The company serves the molecular tools, such as research and diagnostics, and biomanufacturing markets. It operates in Norway, Germany, Lithuania, France, Italy, the United Kingdom, rest of Europe, the United States, and internationally. The company was formerly known as Biotec Pharmacon ASA and changed its name to ArcticZymes Technologies ASA in June 2020. ArcticZymes Technologies ASA was founded in 1990 and is headquartered in Tromsø, Norway.

https://www.arcticzymes.com

Stock Price

NOK0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A

Finn Analysis

(Last Updated 2023-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Very High

0.25

Low 50

High 10

Investors

* Institutions hold a combined 0.00% of the total shares of Arcticzymes Technologies ASA

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

0.06

Latest Release

Date

2025-09-30

EPS Actual

0.0646

EPS Estimate

0.04

EPS Difference

0.0246

Surprise Percent

61.5%

Investing Fit Scorecard

(Last Updated 2023-09-30)

Deep Value
Weak Deep Value(3)
Defensive
Moderately Defensive(5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
No Clear Moat(1.5)
GARP
Not Attractive for GARP(0)
Growth
Weak Growth Prospect(0)
Momentum
No Momentum(2.5)
Net Net
Not Undervalued (Net-Net)(0)
Quality
Low Quality Business(0.5)
Value
Fair Value(4.5)

Income Statement

(Last Updated 2023-09-30)

Revenue

NOK 0

Cost Of Revenue

NOK 0

Gross Profit

NOK 0

Operating Expenses

NOK 0

Operating Income

NOK 0

Interest Expense

NOK 0

Pretax Income

NOK 0

Net Income

NOK 0

Income Tax Expense

NOK 0

EBITDA

NOK 0

Total Other Income Expense Net

NOK 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2023-09-30)

Cash

NOK 0

Short Term Investments

NOK 0

Receivables

NOK 0

Inventories

NOK 0

Total Current Assets

NOK 0

Property Plant Equipment

NOK 0

Total Assets

NOK 0

Payables

NOK 0

Short Term Debt

NOK 0

Long Term Debt

NOK 0

Total Liabilities

NOK 0

Equity

NOK 0

Trend

Cash Flow

(Last Updated 2023-09-30)

Net Income

NOK 0

Depreciation

NOK 0

Change In Working Capital

NOK 0

Cash From Operations

NOK 0

Capital Expenditures

NOK 0

Cash From Investing

NOK 0

Cash From Financing

NOK 0

Net Change In Cash

NOK 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.